Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2002 Nov 12;22(4):309–325. doi: 10.1016/0166-3542(93)90040-P

Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection☆

Gregory H Tignor 1,∗, Catherine A Hanham 1
PMCID: PMC7172876  PMID: 8279818

Abstract

After intraperitoneal (i.p.) infection of infant mice with CCHF virus, virus titers in liver remained significantly higher than in other organs except blood (serum). Within the liver, virus antigen was first found by immunofluorescence (IFA) in Kupffer cells followed by more extensive hepatic spread. Later, virus was found in other organs including brain and heart. Ribavirin treatment significantly reduced infant mouse mortality and extended the geometric mean time to death. Ribavirin treatment reduced CCHF virus growth in liver and significantly decreased, but did not prevent, viremia. Despite a substantial viremia, infection of other organs including brain and heart was not detected in ribavirin-treated mice. A hepatotropic virus subpopulation with less neurovirulence than the parent was isolated from liver of ribavirin-treated mice (single dose, 100 mg/kg). After serial passage in placebo-treated mice, the exclusive hepatotropism was lost.

Keywords: Ribavirin; CCHF, Crimean-Congo hemorrhagic fever; Virus infection

Footnotes

☆

Paper submitted in context of the World Health Organization (WHO)/Pan American Health Organization (PAHO) Meeting on Antiviral Drug Treatment of Viral Haemorrhagic Fevers, Washington DC, USA, 15–16 April 1993.

References

  1. Appleyard G., Way H. Thiosemicarbazone-resistant rabbitpox virus. Br. J. Exp. Pathol. 1966;47:144. [PMC free article] [PubMed] [Google Scholar]
  2. Casals J., Tignor G.H. The Nairovirus genus: serological relationship. Intervirology. 1980;14:144–147. doi: 10.1159/000149175. [DOI] [PubMed] [Google Scholar]
  3. Catlin D.H., Smith R.A., Samuels A.I. 14C-ribavirin: distribution and pharmacokinetics studies in rats, baboons and man. In: Smith R.A., Kirkpatrick W., editors. Ribavirin: a broad spectrum antiviral agent. Academic Press; New York: 1980. pp. 83–89. [Google Scholar]
  4. Centers for Disease Control, National Institutes of Health . Biosafety in Microbiological and Biomedical Laboratories. US Department of Health and Human Services, US Government Printing Office; Washington: 1984. Arboviruses; pp. 77–78. [Google Scholar]
  5. Eriksson B., Helgstrand E., Johansson N., Larsson A., Misiorny A., Noren J.O., Philipson L., Stenberg K., Stening G., Stridh S. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents. Chemother. 1977;11:946–951. doi: 10.1128/aac.11.6.946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ferrara E.A., Oishi J.S., Wannemacher R.W., Jr., Stephen E.L. Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and Rhesus monkeys. Antimicrob. Agents Chemother. 1981;19:1042–1049. doi: 10.1128/aac.19.6.1042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Field H.J. Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy. Antimicrob. Agents Chemother. 1982;21:744. doi: 10.1128/aac.21.5.744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Field H.J. The development of antiviral drug resistance. In: Field H.J., editor. Antiviral Agents: The Development and Assessment of Antiviral Chemotherapy. CRC Press; Florida: 1988. pp. 127–149. [Google Scholar]
  9. Field H.J., Coen D.M. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J. Virol. 1986;60:286–289. doi: 10.1128/jvi.60.1.286-289.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gear J.H.S. Crimean-Congo Hemorrhagic Fever. In: Gear J.H.S., editor. CRC Handbook of Viral and Rickettsial Hemorrhagic Fevers. CRC Press; Florida: 1988. pp. 121–129. [Google Scholar]
  11. Gilbert B.E., Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. 1986;30:201–205. doi: 10.1128/aac.30.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Goswami B.B., Borek F., Sharma O.K., Fujitaki J., Smith R.A. The broad-spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 1979;89:830–836. doi: 10.1016/0006-291x(79)91853-9. [DOI] [PubMed] [Google Scholar]
  13. Grunert R.R. Search for antiviral agents. Annu. Rev. Microbiol. 1979;33:335–353. doi: 10.1146/annurev.mi.33.100179.002003. [DOI] [PubMed] [Google Scholar]
  14. Hall C.B., McBride J.T., Walsh E.E., Bell D.M., Gala C.L., Hildreth S., Eyck L.G.T., Hall W.J. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind studyN. Engl. J. Med. 1983;308:1443–1447. doi: 10.1056/NEJM198306163082403. [DOI] [PubMed] [Google Scholar]
  15. Hanham C.A., Zhao F., Tignor G.H. Evidence from the antiidiotypic network that the acetylcholine receptor is a rabies virus receptor. J. Virol. 1993;67:530–542. doi: 10.1128/jvi.67.1.530-542.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Herrmann E.C., Herrmann J.A. A working hypothesis-virus resistance development as an indicator of specific antiviral activity. Ann. N.Y. Acad. Sci. 1977;284:632–637. doi: 10.1111/j.1749-6632.1977.tb21997.x. [DOI] [PubMed] [Google Scholar]
  17. Ho M., Springer T.A. Mac-1 antigen: Quantitative expression in macrophage populations and tissues, and immunofluorescent localization in spleen. J. Immunol. 1982;128:2281–2286. [PubMed] [Google Scholar]
  18. Hoogstraal H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia. Europe and Africa. J. Med. Entomol. 1979;15:307–417. doi: 10.1093/jmedent/15.4.307. [DOI] [PubMed] [Google Scholar]
  19. Huggins J.W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev. Infect. Dis. 1989;11(Suppl. 4):S750–S761. doi: 10.1093/clinids/11.supplement_4.s750. [DOI] [PubMed] [Google Scholar]
  20. Jahrling P.B., Hess R.A., Eddy G.A., Johnson K.M., Callis R.T., Stephen E.L. Lassa virus infection in rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infec. Dis. 1980;141:580–589. doi: 10.1093/infdis/141.5.580. [DOI] [PubMed] [Google Scholar]
  21. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature. 1975;256:495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  22. McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., Elliott L.H., Belmont-Williams R. Lassa fever. Effective therapy with RibavirinN. Engl. J. Med. 1986;314:20–26. doi: 10.1056/NEJM198601023140104. [DOI] [PubMed] [Google Scholar]
  23. Monath T.P. Ribavirin, interferon, and antibody approaches to the prophylaxis and therapy of the viral hemorrhagic fevers. Curr. Opinion Infect. Dis. 1990;3:824–833. [Google Scholar]
  24. Oxford J.S., Logan I.S., Potter C.W. In vivo selection of an influenza A2 strain resistant to amantadine. Nature. 1970;226:82. doi: 10.1038/226082a0. [DOI] [PubMed] [Google Scholar]
  25. Robins R.K. Synthetic antiviral agents. Chem. Engineer. News. 1986;64:135–146. [Google Scholar]
  26. Ruebner B., Miyai K. The Kupffer cell reaction in murine and human viral hepatitis with particular reference to the origin of acidophilic bodies. Am. J. Pathol. 1962;40:425–435. [PMC free article] [PubMed] [Google Scholar]
  27. Shope R.E., Causey O.R. Further studies on the serological relationships of group C arthropod-borne viruses and the application of these relationships to rapid identification of types. Am. J. Trop. Med. Hyg. 1962;11:283–290. doi: 10.4269/ajtmh.1962.11.283. [DOI] [PubMed] [Google Scholar]
  28. Shope R.E. Arboviruses. In: Lennette E.H., Spaulding E.H., Truant J.P., editors. Manual of Clinical Microbiology. 2nd Edn. American Society for Microbiology; Washington, DC: 1974. pp. 740–745. [Google Scholar]
  29. Spitz M., Spitz L., Thorpe R., Eugui E. Intrasplenic primary immunization for production of monoclonal antibodies. J. Immunol. 1984;70:39–43. doi: 10.1016/0022-1759(84)90387-9. [DOI] [PubMed] [Google Scholar]
  30. Stephen E.L., Jones D.E., Peters C.J., Eddy G.A., Loizeaux P.S., Jahrling P.B. Ribavirin treatment of toga-, arena-, and bunyavirus infections in subhuman primates and other animal species. In: Smith R.A., Kirkpatrick W., editors. Ribavirin: a broad spectrum antiviral agent. Academic Press; New York: 1980. pp. 169–183. [Google Scholar]
  31. Swanepoel R., Gill D.E., Shepherd A.J., Leman P..A., Mynhardt J.H., Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev. Infect. Dis. 1989;11(Suppl. 4):S794–S800. doi: 10.1093/clinids/11.supplement_4.s794. [DOI] [PubMed] [Google Scholar]
  32. Swanepoel R., Leman P., Abbott J.C., Burt F.J., Grobbeleaar A.A. Proc. VIIIth Intl. Cong. Virol. (Berlin) 1990. Epidemiology, diagnosis, clinical pathology and treatment of Crimean-Congo Haemorrhagic Fever (CCHF) in South Africa; p. 430. Abstr. P70-003. [Google Scholar]
  33. Tignor G.H., Smith A.L., Casals J., Ezeokoli C.D., Okoli J. Close relationship of Crimean hemorrhagic fever-Congo (CHF-C) strains by neutralizing antibody assays. Am. J. Trop. Med. Hyg. 1980;29:676–685. doi: 10.4269/ajtmh.1980.29.676. [DOI] [PubMed] [Google Scholar]
  34. Tignor G.H., Shope R.E., Bhatt P.N., Percy D.H. Experimental infection of dogs and monkeys with two rabies serogroup viruses, Lagos bat and Mokola (IbAn27377) Clinical, serologic, virologic, and fluorescent-antibody studiesJ. Infect. Dis. 1973;128:471–478. doi: 10.1093/infdis/128.4.471. [DOI] [PubMed] [Google Scholar]
  35. Van-de-Wal B.W., Joubert J.R., van-Eeden P.J., King J.B. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. S. Afr. Med. J. 1985;68:729–732. [PubMed] [Google Scholar]
  36. Van-Eeden P.J., Van-Eeden S.F., Joubert J.R., King J.B., Van-de-Wal B.W., Michell W.L. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part II. Management of patientsS. Afr. Med. J. 1985;68:718–721. [PubMed] [Google Scholar]
  37. Watts D.M., Ksiazek T.G., Linthicum K.J., Hoogstraal H. Crimean-Congo hemorrhagic fever. In: Monath T.P., editor. Vol. 2. CRC Press; Florida: 1988. pp. 177–222. (The arboviruses: epidemiology and ecology). [Google Scholar]
  38. Wilkinson L. Systat; Evanston, IL: 1989. (SYSTAT: The System for Statistics). [Google Scholar]
  39. Wilson S.Z., Gilbert B.E., Quarles J.M., Knight V., McClung H.W., Moore R.V., Couch R.B. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob. Agents Chemother. 1984;26:200–203. doi: 10.1128/aac.26.2.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wray S.K., Gilbert B.E., Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 1985;5:39–48. doi: 10.1016/0166-3542(85)90013-0. [DOI] [PubMed] [Google Scholar]

Articles from Antiviral Research are provided here courtesy of Elsevier

RESOURCES